You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Login
Username:

Password:


Related Headlines

Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial

Innovent reports first participant dosed in Phase 3 trial of IBI354 for first-line treatment of HER2-positive breast cancer

Amgen wins European approval for Uplizna in generalised myasthenia gravis

Celyad Oncology sells C-Cathez catheter to CellProthera

Akeso's AK139 Phase II clinical trials approved in China

Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris

IP Group plc portfolio company Microbiotica reports positive Phase 1b data for MB310 in ulcerative colitis

Ribo and Madrigal sign global siRNA licensing deal

Galderma launches Restylane Defyne and Refyne in Japan

Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit

AsymBio builds integrated platforms across biopharmaceutical development lifecycle

Evogene expands Google Cloud collaboration to integrate AI agents into ChemPass AI

Cumulus Neuroscience enters Japanese market with Shionogi collaboration

FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1

Eli Lilly signs definitive agreement to acquire Orna Therapeutics

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026